Mimedx (MDXG) Liabilities and Shareholders Equity (2010 - 2026)

Mimedx (MDXG) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $308.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 14.15% year-over-year to $308.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 25.09% YoY), and the FY2025 full-year result was $342.7 million, up 29.83% from the prior year.
• Liabilities and Shareholders Equity retreated to $308.7 million in Q1 2026, from $342.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $342.7 million in Q4 2025 to a low of $168.2 million in Q1 2023.
• A 5-year average of $232.4 million and a median of $230.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slipped 9.87% in 2022 and jumped 39.44% in 2023, its largest moves.
• Tracing MDXG's Liabilities and Shareholders Equity over 5 years: stood at $171.4 million in 2022, then soared by 39.44% to $239.0 million in 2023, then rose by 10.4% to $263.9 million in 2024, then climbed by 29.83% to $342.7 million in 2025, then dropped by 9.92% to $308.7 million in 2026.
• Business Quant data shows MDXG's Liabilities and Shareholders Equity at $308.7 million in Q1 2026, $342.7 million in Q4 2025, and $319.0 million in Q3 2025.